NICE backs restricted use of Alexion’s Strensiq
Cost regulators for NHS treatments in England and Wales have recommended use of Alexion’s Strensiq to treat a rare and often fatal condition called hypophosphatasia (HPP), but have restricted its reach to children with certain forms of the condition.
Read More
